3 days popular7 days popular1 month popular3 months popular

Targeting Dengue Virus Using Artificial MicroRNAs

Mosquito-borne dengue viruses cause an estimated 50 million cases of human a year and are a significant public health threat worldwide. A novel therapeutic approach prevents from reproducing in humans by targeting and silencing key regions of the dengue genome essential for viral replication. This innovative treatment strategy and the successful results of initial testing are presented in Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers. The article is available on the Nucleic Acid Therapeutics website.*

Pei-wen Xie, , Xiu-juan Zhang, Hai Huang, Li-na He, Xue-jun Wang, and Sheng-qi Wang, and Second Artillery General Hospital, Beijing, and Central South University, Changsha, China, identified multiple regions in the that have maintained the same nucleic sequence over long periods of evolution. These highly conserved regions are ideal targets for antiviral drug development as they are unlikely to mutate and allow the virus to develop drug resistance.

In the article “Inhibition of Dengue Virus 2 Replication by Artificial MicroRNAs Targeting the Conserved Regions,” ** the authors describe how they constructed artificial short strands of nucleic acids called microRNAs that specifically target these conserved sites in the dengue virus genome. Their experiments led to the identification of the most effective combinations of microRNAs capable of inhibiting the virus from replication in humans.

“The dengue virus is endemic in over 100 countries and spreading rapidly,” says Executive Editor Fintan Steele, PhD, SomaLogic, Inc., Boulder, CO. “In the absence of effective preventive measures, new treatments like those being pursued by Xie et al. are desperately needed.”



** http://online.liebertpub.com/doi/full/10.1089/nat.2012.0405

Nucleic Acid Therapeutics is under the editorial leadership of Co-Editors-in-Chief Bruce A. Sullenger, PhD, Duke Translational Research Institute, Duke University Medical Center, Durham, NC, and C.A. Stein, MD, PhD, City of Hope National Medical Center, Duarte, CA; and Executive Editor Fintan Steele, PhD (SomaLogic, Boulder, CO).

Mary Ann Liebert, Inc./Genetic Engineering News